977 total citations 31 papers, 470 citations indexed
About
Dao-zhen Xu is a scholar working on Hepatology, Epidemiology and Rheumatology.
According to data from OpenAlex, Dao-zhen Xu has authored 31 papers receiving a total of 470 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hepatology, 22 papers in Epidemiology and 5 papers in Rheumatology. Recurrent topics in Dao-zhen Xu's work include Hepatitis C virus research (23 papers), Hepatitis B Virus Studies (22 papers) and Liver Disease Diagnosis and Treatment (11 papers). Dao-zhen Xu is often cited by papers focused on Hepatitis C virus research (23 papers), Hepatitis B Virus Studies (22 papers) and Liver Disease Diagnosis and Treatment (11 papers). Dao-zhen Xu collaborates with scholars based in China, Hong Kong and Switzerland. Dao-zhen Xu's co-authors include Yu‐Mei Wen, Kai Zhao, Zhenghong Yuan, Qingfeng Sun, Bo‐Jian Zheng, Shuhui Sun, Xin Yao, Jie Zhou, Limin Guo and Wenxiang Wang and has published in prestigious journals such as PLoS ONE, Journal of Hepatology and Vaccine.
Citations per year, relative to Dao-zhen Xu Dao-zhen Xu (= 1×)
peers
Andrew de la Torre
Countries citing papers authored by Dao-zhen Xu
Since
Specialization
Citations
This map shows the geographic impact of Dao-zhen Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dao-zhen Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dao-zhen Xu more than expected).
This network shows the impact of papers produced by Dao-zhen Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dao-zhen Xu. The network helps show where Dao-zhen Xu may publish in the future.
Co-authorship network of co-authors of Dao-zhen Xu
This figure shows the co-authorship network connecting the top 25 collaborators of Dao-zhen Xu.
A scholar is included among the top collaborators of Dao-zhen Xu based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Dao-zhen Xu. Dao-zhen Xu is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Li, Minghui, Yao Xie, Guo‐Hua Qiu, et al.. (2011). [The relationship of serum HBsAg, HBeAg concentration and HBV-DNA load in chronic hepatitis B during IFN treatment].. PubMed. 25(1). 26–8.2 indexed citations
4.
Sun, Qingfeng, Jiguang Ding, Xiaofeng Wang, et al.. (2010). Efficacy and safety of intravenous stronger neo-minophagen C and S-adenosyl-L-methionine in treatment of pregnant woman with chronic hepatitis B: a pilot study.. PubMed. 16(8). PR9–14.3 indexed citations
Wang, Xuanyi, Xin Yao, Limin Guo, et al.. (2009). [Advances on antigen-antibody immunogenic complex therapeutic vaccine for viral hepatitis B].. PubMed. 17(9). 718–20.2 indexed citations
7.
Ren, Hong, et al.. (2009). [Results of 3 years of continuous entecavir treatment in nucleos(t)ide-naive chronic hepatitis B patients].. PubMed. 17(12). 881–6.10 indexed citations
Li, Minghui, Yao Xie, Hui Zhao, et al.. (2006). [Retreatment with interferon of relapsed chronic hepatitis C patients].. PubMed. 14(1). 3–6.1 indexed citations
11.
Liu, Shunai, Dao-zhen Xu, Jianping Zhang, et al.. (2006). [Immune response for phase I clinical trial of a hepatitis B immunogenic complex therapeutic vaccine, YIC].. PubMed. 14(2). 89–92.2 indexed citations
12.
Sun, Qingfeng, et al.. (2006). [The impact of HBeAg positivity/negativity and HBV DNA loads on the prognosis of chronic severe hepatitis B].. PubMed. 14(6). 410–3.6 indexed citations
13.
Zhu, Mei, et al.. (2006). [A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B].. PubMed. 45(11). 891–5.9 indexed citations
14.
Xie, Yao, Dao-zhen Xu, Zhi‐Meng Lu, et al.. (2005). Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial.. PubMed. 4(2). 213–9.18 indexed citations
15.
Xie, Yao, et al.. (2004). [The difference in distribution of HCV genotypes between patients infected with HCV by transfusion and non-transfusion routes].. PubMed. 18(3). 247–50.5 indexed citations
Xie, Yao, Dao-zhen Xu, Zhi‐Meng Lu, et al.. (2004). [The influence of HCV genotype on the IFN treatment of patients with chronic hepatitis C].. PubMed. 12(2). 72–5.3 indexed citations
18.
Xie, Yao, et al.. (2004). [Studies on IgG antibodies of SARS patients].. PubMed. 18(1). 51–3.1 indexed citations
19.
Yan, Jie, et al.. (2003). [Predictors associated with clinical deterioration in SARS patients].. PubMed. 17(3). 222–4.1 indexed citations
20.
Guo, Limin, Jingyuan Liu, Dao-zhen Xu, et al.. (2003). [The treatment of molecular adsorbents recirculating system artificial liver in severe liver failure patients with multiple organ dysfunction syndrome].. PubMed. 11(8). 455–7.14 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.